糖尿病性胃不全麻痺治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Diabetic Gastroparesis - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0808
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Diabetic Gastroparesis – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis – Pipeline Review, H1 2020, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 3, 6 and 1 respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Gastroparesis – Overview
Diabetic Gastroparesis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Diabetic Gastroparesis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Gastroparesis – Companies Involved in Therapeutics Development
AlfaSigma SpA
Allergan Plc
Atlantic Healthcare Plc
Bird Rock Bio Inc
Censa Pharmaceuticals Inc
CinRx Pharma LLC
ETX Pharma Inc
Evoke Pharma Inc
Johnson & Johnson
Takeda Pharmaceutical Co Ltd
Vanda Pharmaceuticals Inc
Diabetic Gastroparesis – Drug Profiles
CIN-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNSA-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metoclopramide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nimacimab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
renzapride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-906 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tradipitant – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
velusetrag – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diabetic Gastroparesis – Dormant Projects
Diabetic Gastroparesis – Discontinued Products
Diabetic Gastroparesis – Product Development Milestones
Featured News & Press Releases
Jan 21, 2020: FDA accepts Evoke Pharma’s NDA resubmission for Gimoti
Dec 20, 2019: Evoke resubmits Gimoti new drug application to FDA
Sep 17, 2019: Evoke Pharma completes manufacturing of commercial scale registration batches of Gimoti
Aug 08, 2019: Evoke Pharma to resubmit Gimoti NDA based on FDA Meeting minutes and announces second quarter 2019 financial results
Jun 27, 2019: Evoke Pharma requests Type A FDA meeting to plan for resubmission of Gimoti NDA
May 17, 2019: Allergan expands PLEDGE Clinical Research Program in Diabetic Gastroparesis
Apr 02, 2019: Evoke Pharma receives complete response letter and recommendations to address deficiencies from FDA for Gimoti NDA
Jan 07, 2019: Evoke Pharma signs commercial and financial agreement for its Lead Product Gimoti in the U.S. with Novos Growth Partners
Dec 03, 2018: Vanda announces positive phase II study results for Tradipitant in patients with gastroparesis
Oct 08, 2018: Allergan to present data on Relamorelin at ACG 2018
Aug 16, 2018: Evoke Pharma’s Gimoti NDA Accepted for FDA Review
Jun 04, 2018: Evoke Announces FDA Submission of New Drug Application for Gimoti
May 15, 2018: EndoLogic Announces FDA Accepts Cardiac Safety Trial for Renzapride in Patients with Gastroparesis
May 10, 2018: Evoke Granted Gender Specific Patent for Gimoti in Mexico
Apr 30, 2018: Evoke Granted First Gender Specific Patent for Gimoti
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Diabetic Gastroparesis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Diabetic Gastroparesis - Pipeline by AlfaSigma SpA, H1 2020
Diabetic Gastroparesis - Pipeline by Allergan Plc, H1 2020
Diabetic Gastroparesis - Pipeline by Atlantic Healthcare Plc, H1 2020
Diabetic Gastroparesis - Pipeline by Bird Rock Bio Inc, H1 2020
Diabetic Gastroparesis - Pipeline by Censa Pharmaceuticals Inc, H1 2020
Diabetic Gastroparesis - Pipeline by CinRx Pharma LLC, H1 2020
Diabetic Gastroparesis - Pipeline by ETX Pharma Inc, H1 2020
Diabetic Gastroparesis - Pipeline by Evoke Pharma Inc, H1 2020
Diabetic Gastroparesis - Pipeline by Johnson & Johnson, H1 2020
Diabetic Gastroparesis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Diabetic Gastroparesis - Pipeline by Vanda Pharmaceuticals Inc, H1 2020
Diabetic Gastroparesis - Dormant Projects, H1 2020
Diabetic Gastroparesis - Discontinued Products, H1 2020

【掲載企業】

AlfaSigma SpA
Allergan Plc
Atlantic Healthcare Plc
Bird Rock Bio Inc
Censa Pharmaceuticals Inc
CinRx Pharma LLC
ETX Pharma Inc
Evoke Pharma Inc
Johnson & Johnson
Takeda Pharmaceutical Co Ltd
Vanda Pharmaceuticals Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[糖尿病性胃不全麻痺治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆